Thank you!

UCB thanks all the participants of this study and their caregivers. All the participants and caregivers helped the researchers learn more about using levetiracetam in Japanese participants with epilepsy. Levetiracetam is also called Keppra®.

This is a summary of the main results of this study. An independent, non-profit organization called CISCRP helped prepare this summary of the study results.

We think it is important to share the results with the participants, their caregivers, and the public. We hope this summary helps the participants and their caregivers understand and feel proud of their important role in medical research.

The purpose of this summary is only to share information. If you need medical advice, please contact your doctor. If you participated in this study and have questions about the study results, please speak with a study doctor or study staff.

Why was the research needed?

Before a treatment is available to all patients, researchers do clinical studies to get information about how well the treatment works and about how safe it is.

The researchers in this study wanted to learn if levetiracetam worked in a large number of Japanese participants with epilepsy. They also wanted to learn if the participants had any medical problems during the study.

Epilepsy is a brain disorder that causes seizures. The symptoms of seizures can be different for each person but often include uncontrollable shaking and may include loss of consciousness.

Epileptic seizures that start in one area of the brain are known as “partial onset” seizures. In this study, the researchers wanted to find out if levetiracetam helped reduce partial onset seizures in Japanese participants with epilepsy.
What were the main questions studied?

The main questions the researchers wanted to answer in this study were:

- Did levetiracetam affect how many seizures the participants had per week?
- What medical problems did the study doctors think might be related to the study treatments?

Who participated in the study?

There were 213 Japanese male and female participants who joined this study and took treatment. The participants were 16 to 65 years old.

The study included participants who took study treatment in Japan.

In this study, the researchers planned to include participants with epilepsy who:

- Were already taking up to 3 epilepsy medications but were still having uncontrolled seizures
- Had at least 12 partial onset seizures within 12 weeks before starting study treatment, with at least 2 seizures every 4 weeks

Each participant was in the study for just over 8 months, but the whole study lasted for 2.5 years. The study started in January 2001 and ended in July 2003.
What treatments did the participants take?

There were 2 main parts of this study. In Part 1, all of the participants took a placebo as a tablet by mouth twice a day for 12 weeks. The placebo tablets looked like the levetiracetam tablets but did not have any levetiracetam in them. The researchers used the placebo to help make sure the effects they found in the study were actually caused by levetiracetam. All of the participants also took their regular epilepsy medication throughout the entire study.

In Part 2, the participants in this study took either levetiracetam or a placebo twice a day for up to 22 weeks. The participants who took levetiracetam took 1 of 2 different doses of levetiracetam.

In Part 2, none of the participants, caregivers, study doctors, or study staff knew what treatment each participant was taking. UCB staff also did not know. Some studies are done this way because knowing what treatment the participants are taking can affect the results of the study. After the study was completed, UCB learned what treatment each participant took so they could create a report of the results.

The researchers used a computer program to randomly choose if the participants took levetiracetam or the placebo. This helped make sure the treatments were chosen fairly and comparing the results for the treatments was as accurate as possible.

The doses of levetiracetam were measured in milligrams, also known as “mg”.

In Part 2:

- **73 participants** took **1,000 mg** of **levetiracetam** per day
- **71 participants** took **3,000 mg** of **levetiracetam** per day
- **72 participants** took the **placebo**

During the first 4 weeks of Part 2, the participants who took levetiracetam slowly had their dose increased until they reached the full dose the researchers wanted to study. After the first 4 weeks, the participants could have their dose decreased if the study doctors thought it was needed.

During the last 4 weeks of Part 2, the participants who took levetiracetam slowly had their dose decreased until they were taking none.

The chart below shows the treatments the researchers studied in Part 2:

<table>
<thead>
<tr>
<th>1,000 mg of levetiracetam</th>
<th>3,000 mg of levetiracetam</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>73 participants</td>
<td>71 participants</td>
<td>72 participants</td>
</tr>
<tr>
<td>1,000 mg per day of levetiracetam as tablets</td>
<td>3,000 mg per day of levetiracetam as tablets</td>
<td>Tablets that looked like levetiracetam</td>
</tr>
<tr>
<td>Twice a day for up to 22 weeks</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
What happened during this study?

While taking the placebo in Part 1, the participants and their caregivers visited their clinic 4 times. At the first visit, each participant first learned about the study and then decided to join, or their parent or caregiver learned about the study and decided to let the participant join the study. This is called “informed consent”. Then, the study doctors and study staff asked about the participants’ medical history and checked their health to make sure they could join the study. This part lasted 12 weeks. The participants also took their regular epilepsy medication.

At some of these visits, the study doctors:

<table>
<thead>
<tr>
<th>action</th>
<th>description</th>
</tr>
</thead>
<tbody>
<tr>
<td>📊</td>
<td>Kept track of any medical problems reported by the participants or their caregivers, or observed by the study doctors or study staff</td>
</tr>
<tr>
<td>🕵️‍♂️</td>
<td>Took blood and urine samples</td>
</tr>
<tr>
<td>🧠</td>
<td>Checked the participants’ brain health using an electroencephalogram, also called an EEG</td>
</tr>
<tr>
<td>🧠</td>
<td>If needed, took pictures of each participant’s brain using CT or MRI scans</td>
</tr>
</tbody>
</table>

The study doctors also did some of these tests and measurements at different visits throughout the rest of the study.
While taking study treatment in Part 2, the participants and their caregivers visited their clinic up to 8 times. This part of the study lasted for up to 22 weeks.

### The participants:

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>![pill]</td>
<td>Took levetiracetam or the placebo twice a day</td>
</tr>
<tr>
<td>![pill]</td>
<td>Continued taking their regular epilepsy medication</td>
</tr>
<tr>
<td>![clipboard]</td>
<td>Kept track of their seizures in a diary</td>
</tr>
</tbody>
</table>

### The study doctors also:

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>![clipboard]</td>
<td>Asked the participants and their caregivers about their symptoms and quality of life</td>
</tr>
<tr>
<td>![heart]</td>
<td>At some visits, checked the participants’ heart health using an electrocardiogram, also called an ECG</td>
</tr>
</tbody>
</table>

After finishing Part 2 of the study, the participants were given the option to immediately join a different study for levetiracetam. In that study, all of the participants were planned to take levetiracetam. The participants who were taking levetiracetam in this study but chose not to join the new study had their dose of levetiracetam slowly decreased until they were taking none. The participants who did not join the new study could visit their clinic 1 more time. This part of the study lasted for 2 weeks. The study doctors checked the participants’ health and asked about any medical problems they were having.
What were the results of the study?

This is a summary of the main results from this study. These are the results from all the participants combined. The individual results of each participant might be different and are not in this summary.

Deciding which treatments work best usually takes results from several studies. Other studies may provide new information or different results. Always talk to a doctor before making any treatment decisions.

Did levetiracetam affect how many seizures the participants had per week?

Yes. Overall, the participants who took levetiracetam had fewer seizures per week than the participants who took the placebo.

To answer this question, the study doctors counted the number of seizures that the participants had reported during the study. They calculated the average number of seizures per week. Then, the researchers compared the average number of seizures per week for the participants who took levetiracetam to the participants who took the placebo.

The researchers found that:

- the participants who took 1,000 mg per day of levetiracetam had 18.8% fewer seizures per week than the participants who took the placebo
- the participants who took 3,000 mg per day of levetiracetam had 23.0% fewer seizures per week than the participants who took the placebo
What medical problems did the study doctors think might be related to the study treatments?

This section is a summary of the medical problems the participants had during the study that the study doctors thought might be related to the study treatments. In this summary, these medical problems are called “adverse reactions”.

This summary also includes information about serious adverse reactions. An adverse reaction is considered “serious” when it is life-threatening, causes lasting problems, or requires hospital care.

Other studies may or may not show that these medical problems were related to the study treatments. The results from several studies are often needed to decide what medical problems are actually caused by a treatment. Always talk to a doctor before making any treatment decisions.

How many participants had serious adverse reactions?

Serious adverse reactions happened in:

- 1.4% of the participants who took 1,000 mg of levetiracetam. This was 1 out of 72 participants
- None of the participants who took 3,000 mg of levetiracetam
- None of the participants who took the placebo

What serious adverse reactions did the participants have?

The only serious adverse reaction that happened during this study was a seizure lasting longer than 5 minutes.

None of the participants died due to serious adverse reactions.

How many participants had any adverse reactions?

Adverse reactions happened in:

- 30.6% of the participants who took 1,000 mg of levetiracetam. This was 22 out of 72 participants.
- 25.4% of the participants who took 3,000 mg of levetiracetam. This was 18 out of 71 participants.
- 27.1% of the participants who took the placebo. This was 19 out of 70 participants.
What adverse reactions did the participants have?

The table below shows the adverse reactions that happened in 5.0% or more of participants in any treatment group. There were other adverse reactions, but those happened in fewer participants.

<table>
<thead>
<tr>
<th>Adverse reaction</th>
<th>1,000 mg levetiracetam (out of 72 participants)</th>
<th>3,000 mg levetiracetam (out of 71 participants)</th>
<th>Placebo (out of 97 participants)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sleepiness</td>
<td>13.9% (10)</td>
<td>7.0% (5)</td>
<td>5.7% (4)</td>
</tr>
<tr>
<td>Dizziness</td>
<td>6.9% (5)</td>
<td>1.4% (1)</td>
<td>5.7% (4)</td>
</tr>
</tbody>
</table>

How has this study helped patients and researchers?

The results of this study have helped researchers learn more about using levetiracetam in Japanese participants with epilepsy.

Deciding which treatments work best for patients almost always takes results from several studies. This summary shows only the main results from this one study. Other studies may provide new information or different results.

The purpose of this summary is only to share information. If you need medical advice about your own health or situation, please contact your doctor.

The results of this study may be used in other studies to compare levetiracetam with other treatments for people who have epilepsy.

At the time this study ended, further clinical studies in epilepsy with levetiracetam were planned.
Where can I learn more about this study?

You can find more information about this study at the website listed below:

- [https://clinicaltrials.gov/ct2/show/NCT00600509](https://clinicaltrials.gov/ct2/show/NCT00600509)

If you have questions about this study, UCB contact information is available at [https://www.ucb.com/UCBCares](https://www.ucb.com/UCBCares).

**Study Information**

**Protocol Number:** N165

**Study Sponsor:** UCB Japan Co., Ltd., sponsored this study. It is referred to as UCB in this summary.

**Full Study Title:** Bridging Study of L059 (Levetiracetam) in Patients with Epilepsy by Double Blind Method

**National Clinical Study Number:** NCT00600509

**Thank you!**

Participants in clinical studies belong to a large community of people who take part in clinical research around the world. They help researchers answer important health questions and find medical treatments for patients.

**Glossary**

<table>
<thead>
<tr>
<th>Description</th>
<th>Also called</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seizure lasting longer than 5 minutes</td>
<td>Status epilepticus</td>
</tr>
<tr>
<td>Sleepiness</td>
<td>Somnolence</td>
</tr>
</tbody>
</table>

This summary was last updated on 09 May 2022. The final clinical study report is dated 13 December 2006.